A comprehensive view of Ridgeback Biotherapeutics LP. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

A committee of the European Medicines Agency recommends against approval of Merck and Ridgeback Biotherapeutics’ Lagevrio COVID-19 pill because clinical benefit 'could not be demonstrated'; Lagevrio approved in US, UK, Japan, China and other countries
Published: February 24, 2023 by BioPharma Dive
FDA ends positive test requirement to prescribe Paxlovid COVID-19 treatment to adult and pediatric patients, Lagevrio to adults at risk of progressing to severe COVID-19; FDA still recommends using SARS-CoV-2 viral testing to diagnose COVID-19
Published: February 08, 2023 by The American Hospital Association (AHA)
Emergent Biosolutions to manufacture, distribute Ridgeback Biotherapeutics’ Ebola injectable antibody therapy Ebanga ansuvimab-zykl in US, Canada; Ridgeback to remain global access partner for Ebanga in endemic countries
Published: July 11, 2022 by SeeNews Pharmaceuticals
HHS reports sales of Pfizer’s COVID-19 oral antiviral Paxlovid outpaced drugs from other firms; 162,000 Paxlovid courses used in US in past week compared to 20,000 courses of Merck and Ridgeback’s Lagevrio, 16,000 courses of AstraZeneca’s Evusheld
Published: May 27, 2022 by FiercePharma

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count